Assessing the Impact of 89Zr-Girentuximab PET/CT on Stated Management Preferences: Results from an Exploratory Survey of Urologic Oncologists. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1558767326002016?dgcid=rss_sd_all
Assessing the Impact of 89Zr-Girentuximab PET/CT on Stated Management Preferences: Results from an Exploratory Survey of Urologic Oncologists. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S1558767326002016?dgcid=rss_sd_all
“Assessing the Impact of 89Zr-Girentuximab PET/CT on Stated Management Preferences: Results from an Exploratory Survey of Urologic Oncologists.” Clinical Genitourinary Cancer.
@article{article41194,
title = {Assessing the Impact of 89Zr-Girentuximab PET/CT on Stated Management Preferences: Results from an Exploratory Survey of Urologic Oncologists},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1558767326002016?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...